Objective  To investigate the influencing factors of dual antiplatelet therapy of aspirin and clopidogrel combined with atorvastatin calcium tablets on recurrent myocardial infarction (RMI) in patients after percutaneous coronary intervention (PCI).

Methods  Data were retrospectively collected on post-PCI patients treated with dual-antiplatelet therapy (aspirin and clopidogrel) combined with atorvastatin calcium tablets in the Department of Cardiology of Quzhou People's Hospital from October 1st, 2022 to October 31st, 2023. Patients were divided into recurrent myocardial infarction (RMI) group and non-RMI (NRMI) group according to whether they had myocardial infarction (MI) again within 28 d and 12 months. Univariate analysis and multivariate Logistic regression were used to explore the factors influencing RMI in post-PCI patients.

Results  A total of 239 post-PCI patients treated with dual antiplatelet combined with atorvastatin calcium tablets were included in the study, and the incidence of RMI was 12.97%. Univariate analysis showed that the differences in age, medication adherence, postoperative physical activity, diabetes mellitus, hyperlipidaemia, preoperative Killip classification, multibranch lesions, high-sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) between the two groups were statistically significant (P<0.05). The results of multivariate Logistic regression showed that postoperative irregular physical activity, smoking, TC and LDL-C were independent risk factors for RMI in post-PCI patients treated with dual antibiotic combined with atorvastatin calcium tablets.

Conclusion Post-PCI patients should increase physical activity and quit smoking to reduce the incidence of RMI while ensuring the medication adherence.

1.董丹, 孙艳秋, 燕燕. 中国居民2002-2021年急性心肌梗死死亡趋势年龄-时期-队列模型分析[J]. 数理医药学杂志, 2023, 36(10): 721-726. [Dong D, Sun YQ, Yan Y. Acute myocardial infarction mortality among Chinese residents from 2002 to 2021:an age-period-cohort model analysis[J]. Journal of Mathematical Medicine, 2023, 36(10): 721-726.] DOI: 10.12173/j.issn.1004-4337.202306096.

2.付春生, 张浩, 周姝, 等. SYNTAX积分联合血清NT-pro BNP、CK-MB、cTn Ⅰ水平对急性心肌梗死患者PCI术预后的评估价值[J]. 西部医学, 2024, 36(11): 1643-1647. [Fu CS, Zhang H, Zhou S, et al. Value of SYNTAX score combined with serum NT-pro BNP, CK-MB and cTn Ⅰ levels on evaluating the prognosis of AMI undergoing coronary intervention[J]. Medical Journal of West China, 2024, 36(11): 1643-1647.] DOI: 10.3969/j.issn.1672-3511.2024.11.016.

3.贾福运, 高晟玮, 张茜, 等. 参附注射液联合西医常规治疗急性心肌梗死PCI术后有效性及安全性的Meta分析[J]. 药物评价研究, 2023, 46(6): 1323-1333. [Jia FY, Gao  SW, Zhang Q, et al. Meta-analysis of efficacy and safety of Shenfu Injection combined with conventional western medicine in treatment of acute myocardial infarction after PCI[J]. Drug Evaluation Research, 2023, 46(6): 1323-1333.] DOI: 10.7501/j.issn.1674-6376.2023.06.021.

4.Gue YX, Spinthakis N, Farag M, et al. Impact of Preadmission morphine on reinfarction in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a meta-analysis[J]. Clin Pharmacol Ther, 2020, 108(1): 54-62. DOI: 10.1002/cpt.1798.

5.Liu H, Dong A, Wang H. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: a retrospective study[J]. Medicine (Baltimore), 2018, 97(42): e12687. DOI: 10.1097/MD.0000000000012687.

6.中华医学会心血管病学分会. 冠状动脉微血管疾病诊断和治疗中国专家共识(2023版)[J]. 中华心血管病杂志, 2024, 52(5): 460-492. DOI: 10.3760/cma.j.cn112148-20231222-00521.

7.Sankaran S, Dendale P, Coninx K. Evaluating the impact of the HeartHab app on motivation, physical activity, quality of life, and risk factors of coronary artery disease patients: multidisciplinary crossover study[J]. JMIR Mhealth Uhealth, 2019, 7(4): e10874. DOI: 10.2196/10874.

8.Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38): 3720-3826. DOI: 10.1093/eurheartj/ehad191.

9.杨婷婷, 童叶青, 殷晓旭, 等. Morisky 服药依从性量表、家庭 APGAR 问卷在结核病患者中的应用评价[J]. 中国社会医学杂志, 2016, 33(6): 580-582. [Yang TT, Tong YQ, Yin  XX, et al. Evaluation of morisky medication adherence scale and family APGAR applied to patients with tuberculosis[J]. Chinese Journal of Social Medicine, 2016, 33(6): 580-582.] DOI: 10.3969/j.issn.1673-5625.2016.06.024.

10.Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. Atherosclerosis, 2016, 253: 281-344. DOI: 10.1016/j.atherosclerosis.2016.08.018.

11.贺翠, 陈春萍, 赵喜兰, 等. 心肌梗死患者经皮冠状动脉介入治疗后的预后状况观察[J]. 岭南心血管病杂志, 2022, 28(5): 403-406, 416. [He C, Chen CP, Zhao XL, et al. Long-term follow-up observation and predictive factor analysis of complications after percutaneous coronary intervention in patients with myocardial infarction[J]. South China Journal of Cardiovascular Diseases, 2022, 28(5): 403-406, 416.] DOI: 10.3969/j.issn.1007-9688.2022.05.04.

12.张花, 王佩佩, 周爱华. 急性心肌梗死PCI术后再发风险因素分析与预防性护理对策[J]. 齐鲁护理杂志, 2024, 30(5): 43-46. [Zhang H, Wang PP, Zhou AH. Analysis of recurrence risk factors after PCI of acute myocardial infarction and preventive nursing countermeasures[J]. Journal of Qilu Nursing, 2024, 30(5): 43-46.] DOI: 10.3969/j.issn.1006-7256.2024.05.012.

13.高晓津, 杨进刚, 杨跃进, 等. 中国急性心肌梗死患者不同年龄组心血管危险因素分析[J]. 中华医学杂志, 2016, 96(40): 3251-3256. [Gao XJ, Yang JG, Yang YJ, et al. Age-related coronary risk factors in Chinese patients with acute myocardial infarction[J]. National Medical Journal of China, 2016, 96(40): 3251-3256.] DOI: 10.3760/cma.j.issn.0376-2491.2016.40.012.

14.白兴合, 刘平, 冯旭, 等. 老年冠心病PCI术后双联抗血小板干预患者依从性的影响因素及对终点事件的影响[J]. 中华保健医学杂志, 2021, 23(4): 387-389. [Bai XH, Liu P, Feng X, et al. Factors influencing compliance with elderly patients with dual antiplatelet intervention and PCI on endpoint events[J]. Chinese Journal of Health Care and Medicine, 2021, 23(4): 387-389.] DOI: 10.3969/j.issn.1674-3245.2021.04.021.

15.Chen C, Li X, Su Y, et al. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: "Real-world" evidence[J]. Clin Cardiol, 2022, 45(12): 1220-1228. DOI: 10.1002/clc.23898.

16.黄菁, 姚娟, 朱宁, 等. 急性心肌梗死患者PCI术后再发的相关危险因素分析[J]. 华夏医学, 2023, 36(6): 38-43. [Huang J, Yao J, Zhu N, et al. Analysis of related risk factors for readmission after PCI in patients with acute myocardial infarction[J]. Acta Medicinae Sinica, 2023, 36(6): 38-43.] DOI: 10.19296/j.cnki.1008-2409.2023-06-007.

17.李莺, 冯雪, 陈碧云, 等. 冠心病术后患者体力活动与运动能力的相关性分析[J]. 中华现代护理杂志, 2021, 27(20): 2673-2679. [Li Y, Feng X, Chen BY, et al. Correlation of physical activity and exercise ability in patients with coronary heart disease[J]. Chinese Journal of Modern Nursing, 2021, 27(20): 2673-2679.] DOI: 10.3760/cma.j.cn115682-20201022-05864.

18.邹芸, 郑梅. 急性心肌梗死患者PCI术后再发的相关影响因素分析[J]. 中国卫生统计, 2020, 37(3): 452-455. [Zou Y, Zheng  M. Analysis of relevant influencing factors after PCI in patients with acute myocardial infarction[J]. Chinese Journal of Health Statistics, 2020, 37(3): 452-455.] https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTA0MTcwMjI2Eg96Z3dzdGoyMDIwMDMwMzIaCGs5YTlldGd3.

19.中国医师协会内分泌代谢科医师分会, 国家心血管病专家委员会心血管代谢医学专业委员会. 糖尿病患者血脂管理中国专家共识(2024版)[J]. 中华糖尿病杂志, 2024, 16(4): 383-403. DOI: 10.3760/cma.j.cn115791-20240301-00090.

20.中国胆固醇教育计划委员会. 高甘油三酯血症及其心血管风险管理专家共识[J]. 中华心血管病杂志, 2017, 45(2): 108-115. DOI: 10.3760/cma.j.issn.0253-3758.2017.02.008.

21.Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry[J]. Circ Cardiovasc Qual Outcomes, 2016, 9(2): 100-108. DOI: 10.1161/CIRCOUTCOMES.115.002104.

22.Liu J, Wang W, Wang M, et al. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese multi-provincial cohort study[J]. Diabetes Res Clin Pract, 2012, 96(2): 217-224. DOI: 10.1016/j.diabres.2011.12.018.

23.郭建君, 郭航远, 池菊芳,等. 吸烟对心血管疾病的影响及最新进展[J]. 中国全科医学, 2017, 20(27): 3328-3331. [Guo JJ, Guo HY, Chi JF, et al. Impact of smoking on cardiovascular disease and its recent progress[J]. Chinese General Practice, 2017, 20(27): 3328-3331.] DOI: 10.3969/j.issn.1007-9572.2017.00.034.

24.傅绪杰, 邵建华. Killip分级在老年急性心肌梗死预后判断中的价值[J]. 中华老年心脑血管病杂志, 2001, 3(4): 243. [Fu  XJ, Shao JH. The value of Killip grade in judging the prognosis of acute myocardial infarction in the elderly[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2001, 3(4): 243.] DOI: 10.3969/j.issn.1009-0126.2001.04.024.

25.陈冬生, 栾献亭, 杨进刚, 等. 中国急性心肌梗死不同Killip分级患者的临床特征、治疗和预后情况分析[J]. 中国循环杂志, 2016, 31(9): 849-853. [Chen DS, Luan XT, Yang JG, et al. Analysis of clinical features, treatment and prognosis in acute myocardial infarction patients with different Killip grades in China[J]. Chinese Circulation Journal, 2016, 31(9): 849-853.] DOI: 10.3969/j.issn.1000-3614.2016.09.005.

26.沈思思. 多支血管病变对急性心肌梗死患者短期预后的影响 [D]. 杭州: 浙江大学, 2013. https://cdmd.cnki.com.cn/Article/CDMD-10335-1013374686.htm.

27.樊刚, 王忠, 王丽, 等. 预防性经皮冠状动脉介入治疗术对多支血管病变ST段抬高型心肌梗死患者预后影响的Meta分析[J]. 中国全科医学, 2016, 19(25): 3120-3128. [Fan G, Wang  Z, Wang L, et al. Prognostic effects of preventive percutaneous coronary intervention in ST - segment elevation myocardial infarction patients with multivessel disease:a Meta-analysis[J]. Chinese General Practice, 2016, 19(25): 3120-3128.] DOI: 10.3969/j.issn.1007-9572.2016.25.025.

28.Carrero JJ, Andersson Franko M, Obergfell A, et al. hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study[J]. J Am Heart Assoc, 2019, 8(11): e012638. DOI: 10.1161/JAHA.119.012638.

29.Nikorowitsch J, Ojeda F, Lackner KJ, et al. Head-to-head comparison of the incremental predictive value of the three established risk markers, Hs-troponin I, C-reactive protein, and NT-proBNP, in coronary artery disease[J]. Biomolecules, 2020, 10(3): 394. DOI: 10.3390/biom10030394.